ST316

Sapience Therapeutics will present Phase 2 clinical trial data for lucicebtide, a first-in-class C/EBPβ antagonist, in glioblastoma patients at the 2025 ASCO Annual Meeting.

The FDA has granted Orphan Drug Designation to ST316, a β-catenin antagonist, for treating familial adenomatous polyposis (FAP).

Sapience Therapeutics has initiated a Phase 2 clinical trial for ST316, a peptide therapeutic, in patients with advanced or metastatic solid tumors.

Sapience Therapeutics will participate in the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum on October 8-9, 2024.

Sapience Therapeutics has dosed the first patient in its Phase 2 dose expansion study of ST316, a first-in-class β-catenin antagonist, for colorectal cancer.